Burden of type 2 diabetes from the healthcare payer perspective in Slovenia

Zdravstveno Varstvo

Volumn 52, Issue 3, 2013, Pages 162-172

  Nerat, Tomaž ^a   Kos, Mitja ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Complications; Cost of illness; Diabetes Mellitus; Health expenditures; Public health; Slovenia; Type 2

Indexed keywords

EID: 84881493781     PISSN: 03510026     EISSN: 18542476     Source Type: Journal    
DOI: 10.2478/sjph-2013-0018     Document Type: Article

References (63)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14.
2. Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, Nichols G. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 293-301.
3. Jelic J, Drinovec J, Mrhar A. Burden of type 2 diabetes. Farm vest 2006; 5: 316-324.
4. Nacionalni program za obvladovanje sladkorne bolezni, strategija razvoja 2010 -2020, November 2009. Available October 15, 2011 from: http://www.mz.gov. si/fileadmin/mz.gov.si/pageuploads/mz-dokumenti/zakonodaja/NP-diabetes/ Nacionalni-program-obvladovanja-sladkorne-bolezni-210410.pdf
5. Slovenian public healtcare expenditures plan for 2011. Available October 27, 2011 from: http://www.zzzs.si/zzzs/info/egradiva. nsf/o/ E0455EFA06C92F42C1257826002F5012?OpenDocu ment
6. Enotni seznam zdravstvenih storitev in samoupravni sporazum o njegovi uporabi v svobodni menjavi dela (Greenbook). Ljubljana, 1982.
7. General agreement for the contract year 2010. Obcasnik ZZZS. Available October 26, 2011 from: http://www.zzzs.si/ZZZS/info/egradiva.nsf/0/ 89fd37d2ebe57302c1257711001b18 00/FILE/Ob%C4%8Dasnik%20Akti%20&%20navodila- 1.%20del-03.05.2010.pdf
8. General agreement for the contract year 2010: design and financing of health services for natural health resorts. Obcasnik ZZZS. Available October 30, 2011 from: http://www.zzzs.si/ZZZS/info/egradiva.nsf/0/ b2a6638bd0a4227cc1257711001b3c 31/FILE/Ob%C4%8Dasnik%20Akti%20&%20navodila- 2.%20del-03.05.2010.pdf
9. Average healthcare prices, from 1.10.2011 on, ZZZS, Ljubljana, 2011. Available October 10, 2011 from: http://www.zzzs.si/zzzs/pao/izvajalci.nsf/o/ C796E9958FE5FC83C12579190011A716
10. Slovenian National Institute of Public Health, Sheet T13 (Number of acute healtcare events grouped by Diagnosis related groups -DRG in 2009). Available October 15, 2011 from: http://www.ivz.si/podatkovne-zbirke?pi=5&-5-Filename= 2086.xls&-5-MediaId=2086&-5-AutoResize=false&pl=46-5.3.
11. Data from The Health Insurance Institute of Slovenia outpatient drug dispense database from the year 2008.
12. Slovenian medicine costs on the day 14.10.2011. JAZMP. Available October 15, 2011 from: http://www.jazmp.si/files/farmakoekonomika/cene-20111014.xls
13. Slovenian National Institute of Public Health. Drug consume database from 2001 to 2010. Available October 11, 2011 from: http://www.zzzs.si/zzzs/ internet/zzzs.nsf/o/CEECE65B19F25E4FC1257552002BEC54
14. The Health Insurance Institute of Slovenia, Medical technical devices database. Available April 24, 2012 from: http://www.zzzs.si/zzzs/info/egradiva. nsf/0/dfdc914987 e44e2ac1257353003ec73a/FILE/SEZNAM%20S%20%C5%A0IFRANTOM,MK, POSTOPKI,CS,%201.3.2012.xls
15. The Health Insurance Institute of Slovenia business report 2011. Available April 24, 2012 from: http://www.zzzs.si/zzzs/info/egradiva.nsf/0/ 59d2866474ebc834c12579e500286886 /FILE/ Poslovno%20poro%C4%8Dilo%20ZZZS%20za%20leto%202011-19.4.2012.pdf
16. Yeaw J, Lee WC, Aagren M, Christensen T. Cost ofselfmonitoring of blood glucose in the United States among patients on an insulin regimen for diabetes. J Manag Care Pharm 2012; 18: 21-32.
17. U.S. Renal Data System, USRDS 2008 Annual Data Report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2008.
18. (The data reported here have been supplied by the United States Renal Data System (USRDS). The interpretation and reporting of these data are the resposibility of the author(s) and in no way should be seen as an official policy or interpretation of the U.S. government.)
19. Postma MJ, de Zeeuw D. The economic benefits of preventing end-stage renal disease in patients with type 2 diabetes mellitus. Nephrol Dial Transplant 2009; 10: 2975-2983.
20. ParraMoncasi E, Arenas Jiménez MD, Alonso M et al. Multicentre study of haemodialysis costs. Nefrologia 2011; 31: 299-307.
21. Villa G, Rodríguez-Carmona A, Fernández-Ortiz L et al. Cost analysis of the Spanish renal replacement therapy programme. Nephrol Dial Transplant 2011; 26: 3709-3714.
22. Haller M, Gutjahr G, Kramar R, Harnoncourt F, Oberbauer R. Cost-effectiveness analysis of renal replacement therapy in Austria. Nephrol Dial Transplant 2011; 26: 2988-2995.
23. Blotière PO, Tuppin P, Weill A, Ricordeau P, Allemand H. The cost of dialysis and kidney transplantation in France in 2007, impact of an increase of peritoneal dialysis and transplantation. Nephrol Ther 2010; 6: 240-247.
24. Tan ML, Feng J, Gordois A, Wong ES. Lower extremity amputation prevention in Singapore: economic analysis of results. Simgapore Med J 2011; 52: 662-668.
25. Davis WA, Norman PE, Bruce DG, Davis TM. Predictors, consequences and costs of diabetes-related lower extremity amputation complicating type 2 diabetes: the fremantle diabetes study. Diabetologia 2006; 49: 2634-2641.
26. O'Brien JA, Patrick AR, Caro JJ. Cost of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Serv Res 2003; 21: 7.
27. Clarke PM, Glasziou P, Patel A, Chalmers J, Woodward M, Harrap SB, Salomon JA. Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis. PLoS Med 2010; 7: e10000236.
28. Szmurlo D, Schubert A, Kostrzewska K, Rys P, Skrzekowska-Baran I. Economic analysis of the implementation of guidelines for type 2 diabetes control developed by Diabetes Poland: what increase in costs is justified by clinical results? Pol Arch Med Wewn 2011; 121: 345-350.
29. Heerey A, McGowan B, Ryan M, Barry M. Microcosting versus DRGs in the provision of cost estimates for use in pharmacoeconomic evaluation. Expert Rev Pharmacoecon Outcomes Res 2002; 2: 29-33.
30. Tiemann O. Variations in hospitalisation costs for acute myocardial infarction -A comparison across Europe. Health Econ 2008; 17: S33-S45.
31. Christensen MC, Previgliano I, Capparelli FJ, Lerman D, Lee WC, Wainsztein NA. Acute treatment costs of intracerebral hemorrhage and ischemic stroke in Argentina. Acta Neurol Scand 2009; 119: 246-253.
32. Luengo-Fernandez R, Gray AM, Rothwell PM. Costs of stroke using patient-level data: a critical review of the literature. Stroke 2009; 40: e18-e23.
33. Thijs V, Dewilde S, Putman K, Pince H. Cost of hospitalization for cerebrovascular disorders in Belgium. Acta Neurol Belg; 2011; 111: 104-110.
34. Truelsen T, Ekman M, Boysen G. Cost of stroke in Europe. Eur J Neurol 2005; 12: 78-84.
35. Frier BM. The economic costs of hypoglycaemia. Br J Diabetes Vasc Dis 2011; 11: S10-S12.
36. Tenerz A, Lönnberg I, Berne C, Nilsson G, Leppert J. Myocardial infarction and prevalence of diabetes mellitus. Is increased casual blood glucose at admission a reliable criterion for the diagnosis of diabetes? Eur Heart J 2001; 22: 1102-1110.
37. Slovenian National Institute of Public Health, Sheet tb3 (Number of deaths grouped by International Classification of Diseases -ICD in 2009). Available October 12, 2011 from: http://www.ivz.si/Mp.aspx?ni=46&pi=5&- 5-id=58&-5-PageIndex=0&-5-groupId=185&-5-newsCategory= &-5-action=ShowNewsFull&pl=46-5.0.
38. Maple-Brown L, Cunningham J, Dunne K, Whitbread C, Howard D, Weeramanthri T, et al. Complicationsof diabetes in urban Indigenous Australians: the DRUID study. Diabetes Res Clin Pract 2008; 80: 455-462.
39. Buturovic-Ponikar J, Adamlje T, Arnol M, Blanusa D, Ceglar Z, Cimerman-Steklasa S et al. Hemodialysis in Slovenia -data from the Slovenian renal replacement therapy registry. Ther Apher Dial 2010; 14: A1-A15.
40. Kandus A, Arnol M, Kovac D. Forty years of renal transplantation in Slovenia. Ther Apher Dial 2010; 14: A1-A15.
41. Palmer AJ, Valentine WJ, Chen R, Mehin N, Gabriel S, Bregman B et al. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant 2008; 23; 1216-1223.
42. Sloan FA, Bethel MA, Lee PP, Brown DS, Feinglos MN. Adherence to guidelines and its effects on hospitalizations with complications of type 2 diabetes. Rev Diabet Stud 2004; 1: 29-38.
43. Buturovic-Ponikvar J et al. Slovenian renal replacement therapy registry: 2006 annual report. Ljubljana: Slovenian Society of Nephrology, 2008.
44. Ponikvar R, Buturovic-Ponikvar J. Dializno zdravljenje. Ljubljana: Klinicni oddelek za nefrologijo, SPS Interna klinika, Klinicni center Ljubljana, 2004.
45. Grego K, Arnol M, Bren AF, Kmetec A, Tomažic J, Kandus A. Basiliximab versus Daclizumab combined with triple immunosuppression in deceased donor renal Graft recipients. Transplant Proc 2007; 39: 3093-3097.
46. Kissela BM, Khoury J, Kleindorfer D, Woo D, Schneider A, Alwell K, Miller R, et al. Epidemiology of ischemic stroke in patients with diabetes: the greater Cincinnati/Northern Kentucky Stroke Study. Diabetes Care 2005; 28: 355-359.
47. G. Veninšek. Diabetes management in Celje general hospital. Zdrav Vest 2001; 70: 7-10.
48. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther 2008; 88: 1254-1264.
49. V. Urbancic. Diabetic foot. Maribor: 3. Congress of family medicine, 2004.
50. Novo A, Jokic I. Medical audit of diabetes mellitus in primary care setting in Bosnia and Herzegovina. Croat Med J 2008; 49: 757-762.
51. Dejager S, Schweizer A. Minimizing the risk of hypoglycemia with vildagliptin: clinical experience, mechanistic basis, and importance in type 2 diabetes management. Diabetes Ther 2011; 2: 51-66.
52. Globocnik-Petrovic M, Urbancic M, Sevšek D. Smernice za presejanje in zdravljenje diabeticne retinopatije. Zdrav Vestn 2010; 79: I7-I18.
53. Rosenberg JB, Friedman IB, Gurland JE. Compliance with screening guidelines for diabetic retinopathy in a large academic children's hospital in the Bronx. J Diabetes Complications 2011; 25: 222-226.
54. Singh P, Aronow WS, Mellana WM, Gutwein AH. Prevalence of appropriate management of diabetes mellitus in an academic general medicine clinic. Am J Ther 2010; 17: 42-45.
55. Fera T, Bluml BM, Ellis WM, Schaller CW, Garrett DG. The diabetes ten city challenge: interim clinical and humanistic outcomes of a multisite community pharmacy diabetes care program. J Am Pharm Assoc 2008; 48: 181-190.
56. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001; 24: 1069-1078.
57. Rubin RR, Ciechanowski P, Egede LE, Lin EH, Lustman PJ. Recognizing and treating depression in patients with diabetes. Curr Diab Rep 2004; 4: 119-125.
58. Ray JA, Valentine WJ, Secnik K, Oglesby AK, Cordony A, Gordois A, Davey P, et al. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Curr Med Res Opin 2005; 21: 1617-1629.
59. Jönsson B; CODE-2 Advisory Board. Revealing the cost of Type II diabetes in Europe. Diabetologia 2002; 45: S5-S12.
60. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008; 31: 596-615.
61. Ballesta M, Carral F, Olveira G, Girón JA, Aguilar M. Economic cost associated with type II diabetes in Spanish patients. Eur J Health Econ 2006; 7: 270-275.
62. Nadathur S, Groom A. Codingand DRG relationships in stroke and transientischaemic attack (TIA). HIM J 2006; 35: 38-44.
63. The Health Insurance Institute of Slovenia. Compulsory health insurance rules. Available September 17, 2012 from: http://www.zzzs.si/zzzs/info/egradiva. nsf/0/5580D0555F5A1FEAC1256CF B003BB45C?OpenDocument